Rankings

Market Cap
Revenue
Operating Income
CapEx
Total Assets
Net Assets
Cash on Hand

Sectors

Technology
Healthcare
Financial Services
Consumer Cyclical
Communication Services
Industrials
Consumer Defensive
Energy
Basic Materials
Real Estate
Utilities

Pages

Home
Earnings Calendar
All Sectors
Terms
Privacy

© 2026 Market Cap Arena. All rights reserved.v1.2.30

CLDXCelldex Therapeutics, Inc.

$2B

Q3 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

-$47M-2101.2% margin

Operating Income

-$30M-1351.0% margin

Net Income

-$30M-1333.2% margin

EPS (Diluted)

$-4.41

QoQ Revenue Growth

+59.8%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$25M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$252M

Total Liabilities

$35M

Stockholders' Equity

$217M

Cash & Equivalents

$32M

Revenue Segments

Pd1 Immune Checkpoint Inhibitor

$500,000100%

← FY 2016 All Quarters Q4 2016 →

CLDX Q3 2016 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena